Marco Astegiano
ISMETT
EpidemiologyInternal medicineSurgeryPathologyRetrospective cohort studyIntensive care medicineProspective cohort studyImmunologyBreath testHelicobacter pyloriInflammatory Bowel DiseasesInflammatory bowel diseaseIrritable bowel syndromeDiseaseCrohn's diseaseAdalimumabUlcerative colitisPopulationIn patientMedicineGastroenterology
236Publications
27H-index
2,814Citations
Publications 232
Newest
#1Davide Giuseppe Ribaldone (UNITO: University of Turin)H-Index: 17
#2Nicola ImperatoreH-Index: 13
Last. Marco AstegianoH-Index: 27
view all 19 authors...
Abstract Background Data regarding the effect of orthotopic liver transplantation (OLT) for primary sclerosing cholangitis (PSC) on inflammatory bowel disease (IBD) course are scarce and conflicting. Aims To compare the incidence of refractory IBD in two groups (OLT and non-OLT) of patients affected by IBD and PSC. Methods An observational, multicentre, cohort retrospective study was conducted by the Italian Group for the study of IBD in Italy. The primary outcome was the need for biologic thera...
Source
Source
Source
#1Valentina PonzoH-Index: 13
#2Ilario FerrocinoH-Index: 26
Last. Simona BoH-Index: 42
view all 14 authors...
The aims of this observational “proof-of-concept” study were to analyze the clinical/psychological characteristics and gut microbiota/mycobiota composition of individuals with suspected non-celiac gluten/wheat sensitivity (NCGS/WS) according to responses to the double-blind-placebo-controlled (DBPC) crossover gluten challenge test. Fifty individuals with suspected NCGS/WS were subjected to the DBPC challenge test; anthropometric measurements, psychometric questionnaires, and fecal samples were c...
Source
#1Chiara RossoH-Index: 23
Last. Davide Giuseppe RibaldoneH-Index: 17
view all 9 authors...
Background and Objectives: Patients affected by inflammatory bowel diseases (IBDs) are complex patients with various problems from a clinical and psychological point of view. This complexity must be addressed by a multidisciplinary team, and an inflammatory bowel disease nurse can be the ideal professional figure to create a link between doctor and patient. The objective of this comprehensive review is to describe the figure of inflammatory bowel disease nurses and the various benefits that thei...
Source
OBJECTIVE The use of antisecretory drugs can provide symptomatic relief in 70-80% of patients suffering from gastro-oesophageal reflux disease (GORD), although this benefit is reduced by 20-30% in the case of nonerosive reflux disease (NERD). The current study evaluates the efficacy and safety of a patented oral formulation (liquid sachets containing hyaluronic acid, a mixture of amino acids including proline, hydroxyl-proline and glutamine, and rice extract dispersed in a bioadhesive polymer ma...
Source
Butyrate is a short-chain fatty acid that plays a key role in maintaining gut homeostasis as well as the integrity of the intestinal barrier. In the present study, we investigated the effect of oral microencapsulated sodium butyrate (BLM) administration in maintaining remission and improving residual symptoms and inflammatory markers in a population of patients with ulcerative colitis (UC). Forty-two patients with UC in clinical remission were enrolled in the study. Three patients were lost to f...
1 CitationsSource
#1Francesco Stalla (UNITO: University of Turin)H-Index: 1
#2Marco AstegianoH-Index: 27
Last. Rinaldo PellicanoH-Index: 28
view all 5 authors...
In recent years, there has been growing interest in the comprehension of the physiology of intestinal permeability and microbiota and how these elements could influence the pathogenesis of diseases. The term intestinal permeability describes all the processes that allow the passage of molecules as water, electrolytes and nutrients through the intestinal barrier by the para-cellular or the trans-cellular transport systems with several implications for self-tolerance and not-self immunity. An incr...
Source
#2Marta Vernero (UNIPV: University of Pavia)H-Index: 5
Last. Marco AstegianoH-Index: 27
view all 3 authors...
We sincerely thank Viscido et al. for their appropriate and sharable comments on our recent study on adalimumab biosimilar ABP 501 in Crohn's disease (CD). The use of a biosimilar in inflammatory disorders is one of the current main topics, given the great opportunity to save resources that can be invested in innovative drugs and the ethical problems that non-medical switching can generate.
Source
Source